메뉴 건너뛰기




Volumn 44, Issue 10, 2012, Pages 2936-2939

Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAPAMYCIN; TELMISARTAN;

EID: 84870174500     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.06.073     Document Type: Article
Times cited : (15)

References (17)
  • 1
    • 0034468489 scopus 로고    scopus 로고
    • Volumetric measurement of renal cysts and parenchyma using MRI: Phantoms and patients with polycystic kidney disease
    • K.T. Bae, P.K. Commean, J. Lee Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease J Comput Assist Tomogr 24 2000 614
    • (2000) J Comput Assist Tomogr , vol.24 , pp. 614
    • Bae, K.T.1    Commean, P.K.2    Lee, J.3
  • 2
    • 12444274302 scopus 로고    scopus 로고
    • Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort
    • A.B. Chapman, L.M. Guay-Woodford, J.J. Grantham Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort Kidney Int 64 2003 1035
    • (2003) Kidney Int , vol.64 , pp. 1035
    • Chapman, A.B.1    Guay-Woodford, L.M.2    Grantham, J.J.3
  • 3
    • 33646678189 scopus 로고    scopus 로고
    • Volume progression in polycystic kidney disease
    • CRISP Investigators
    • J.J. Grantham, V.E. Torres, A.B. Chapman CRISP Investigators Volume progression in polycystic kidney disease N Engl J Med 354 2006 2122
    • (2006) N Engl J Med , vol.354 , pp. 2122
    • Grantham, J.J.1    Torres, V.E.2    Chapman, A.B.3
  • 4
    • 18744380752 scopus 로고    scopus 로고
    • Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease
    • Y. Tao, J. Kim, R.W. Schrier Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease J Am Soc Nephrol 16 2005 46
    • (2005) J Am Soc Nephrol , vol.16 , pp. 46
    • Tao, Y.1    Kim, J.2    Schrier, R.W.3
  • 5
    • 33644859253 scopus 로고    scopus 로고
    • Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)
    • P.R. Wahl, A.L. Serra, M. Le Hir Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD) Nephrol Dial Transplant 3 2006 598
    • (2006) Nephrol Dial Transplant , vol.3 , pp. 598
    • Wahl, P.R.1    Serra, A.L.2    Le Hir, M.3
  • 6
    • 71749087934 scopus 로고    scopus 로고
    • Sirolimus therapy for patients with adult polycystic kidney disease: A pilot study
    • A.R. Soliman, E. Ismail, S. Zamil Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study Transplant Proc 41 2009 3639
    • (2009) Transplant Proc , vol.41 , pp. 3639
    • Soliman, A.R.1    Ismail, E.2    Zamil, S.3
  • 7
    • 84860633618 scopus 로고    scopus 로고
    • Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease
    • Z. Novalic, A.M. van der Wal, W.N. Leonhard Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease J Am Soc Nephrol 23 2012 842
    • (2012) J Am Soc Nephrol , vol.23 , pp. 842
    • Novalic, Z.1    Van Der Wal, A.M.2    Leonhard, W.N.3
  • 8
    • 35748948350 scopus 로고    scopus 로고
    • Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study
    • A.L. Serra, A.D. Kistler, D. Poster Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study BMC Nephrol 8 2007 13
    • (2007) BMC Nephrol , vol.8 , pp. 13
    • Serra, A.L.1    Kistler, A.D.2    Poster, D.3
  • 9
    • 40449138290 scopus 로고    scopus 로고
    • Sirolimus reduces polycystic liver volume in ADPKD patients
    • Q. Qian, H. Du, B.F. King Sirolimus reduces polycystic liver volume in ADPKD patients J Am Soc Nephrol 19 2008 631
    • (2008) J Am Soc Nephrol , vol.19 , pp. 631
    • Qian, Q.1    Du, H.2    King, B.F.3
  • 10
    • 84863937859 scopus 로고    scopus 로고
    • Invited review - Mammalian target of rapamycin and the kidney part II: Pathophysiology and therapeutic implications
    • W. Lieberthal, J.S. Levine Invited review - mammalian target of rapamycin and the kidney part II: pathophysiology and therapeutic implications Am J Physiol Renal Physiol 300 2012 180
    • (2012) Am J Physiol Renal Physiol , vol.300 , pp. 180
    • Lieberthal, W.1    Levine, J.S.2
  • 11
    • 77956029702 scopus 로고    scopus 로고
    • Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
    • A.L. Serra, D. Poster, A.D. Kistler Sirolimus and kidney growth in autosomal dominant polycystic kidney disease N Engl J Med 363 2010 820
    • (2010) N Engl J Med , vol.363 , pp. 820
    • Serra, A.L.1    Poster, D.2    Kistler, A.D.3
  • 12
    • 77956035166 scopus 로고    scopus 로고
    • Everolimus in patients with autosomal dominant polycystic kidney disease
    • G. Walz, K. Budde, M. Mannaa Everolimus in patients with autosomal dominant polycystic kidney disease N Engl J Med 363 2010 830
    • (2010) N Engl J Med , vol.363 , pp. 830
    • Walz, G.1    Budde, K.2    Mannaa, M.3
  • 13
    • 77954770878 scopus 로고    scopus 로고
    • Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases
    • V.E. Torres, A. Boletta, A. Chapman Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases Clin J Am Soc Nephrol 5 2010 1312
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 1312
    • Torres, V.E.1    Boletta, A.2    Chapman, A.3
  • 14
    • 58149171924 scopus 로고    scopus 로고
    • Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months
    • A.D. Kistler, D. Poster, F. Krauer Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months Kidney Int 75 2009 235
    • (2009) Kidney Int , vol.75 , pp. 235
    • Kistler, A.D.1    Poster, D.2    Krauer, F.3
  • 15
    • 77956048123 scopus 로고    scopus 로고
    • MTOR inhibitors in polycystic kidney disease
    • T. Watnick, G. Germino mTOR inhibitors in polycystic kidney disease N Engl J Med 363 2010 879
    • (2010) N Engl J Med , vol.363 , pp. 879
    • Watnick, T.1    Germino, G.2
  • 16
    • 59649126728 scopus 로고    scopus 로고
    • Sirolimus CONVERT Trial Study Group Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial
    • F.P. Schena, M.D. Pascoe, J. Alberu Sirolimus CONVERT Trial Study Group Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
    • (2009) Transplantation , vol.87 , pp. 233
    • Schena, F.P.1    Pascoe, M.D.2    Alberu, J.3
  • 17
    • 78649503269 scopus 로고    scopus 로고
    • Autosomal dominant polycystic kidney disease and mTOR inhibitors: The narrow road between hope and disappointment
    • C. Ponticelli, F. Locatelli Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment Nephrol Dial Transplant 25 2010 3809
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 3809
    • Ponticelli, C.1    Locatelli, F.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.